A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.

David Levitz Yogen Saunthararajah Kateryna Fedorov Lauren C Shapiro Ioannis Mantzaris Aditi Shastri Noah Kornblum R Alejandro Sica Nishi Shah Marina Y Konopleva Kira Gritsman Ira Braunschweig Dennis L Cooper Kith Pradhan Amit K Verma Eric J Feldman Mendel Goldfinger

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

This preliminary clinical experience, although retrospective, provides proof-of-activity of noncytotoxic DNA methyltransferase 1-targeting by allowing frequent, sustained drug exposure often not possible with standard HMA/VEN regimens.

Keyphrases

acute myeloid leukemia
low dose
circulating tumor
high dose
allogeneic hematopoietic stem cell transplantation
cell free
cancer therapy
cross sectional
single molecule
chronic lymphocytic leukemia
adverse drug
emergency department
drug delivery
electronic health record